Cyclerion Therapeutics (CYCN) Common Equity (2018 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Common Equity of $9.1 million for Q4 2025, up 2.66% year-over-year from $8.8 million in Q4 2024, and down 4.75% quarter-over-quarter from $9.5 million in Q3 2025.
Cyclerion Therapeutics (CYCN) Common Equity (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' Common Equity history runs 8 years deep, the most recent figure standing at $9.1 million for Q4 2025.
- In Q4 2025, Common Equity rose 2.66% year-over-year to $9.1 million; the TTM figure through Dec 2025 stood at $9.1 million (up 2.66% YoY), while the FY2025 annual figure was $9.1 million, up 2.66% from the prior year.
- Common Equity for Q4 2025 stood at $9.1 million, down from $9.5 million in the prior quarter.
- The five-year high for Common Equity was $65.2 million in Q2 2021, with the low at $3.9 million in Q1 2023.
- The 5-year median for Common Equity is $10.2 million (2022), against an average of $20.6 million.
- The sharpest annual moves came in 2023 and 2024: Common Equity plunged 89.4% in 2023, then surged 152.82% in 2024.
- Cyclerion Therapeutics' Common Equity stood at $48.2 million in 2021, then tumbled by 78.34% to $10.5 million in 2022, then advanced by 8.0% to $11.3 million in 2023, then fell by 21.6% to $8.8 million in 2024, then grew by 2.66% to $9.1 million in 2025.
- Business Quant data shows CYCN's Common Equity at $9.1 million in Q4 2025, $9.5 million in Q3 2025, and $8.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | 9.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.09 Mn |
| Sep 30, 2025 | 9.54 Mn |
| Jun 30, 2025 | 8.57 Mn |
| Mar 31, 2025 | 8.78 Mn |
| Dec 31, 2024 | 8.85 Mn |
| Sep 30, 2024 | 8.20 Mn |
| Jun 30, 2024 | 8.78 Mn |
| Mar 31, 2024 | 9.92 Mn |
| Dec 31, 2023 | 11.29 Mn |
| Sep 30, 2023 | 12.87 Mn |
| Jun 30, 2023 | 5.15 Mn |
| Mar 31, 2023 | 3.93 Mn |
| Dec 31, 2022 | 10.45 Mn |
| Sep 30, 2022 | 16.52 Mn |
| Jun 30, 2022 | 25.36 Mn |
| Mar 31, 2022 | 37.03 Mn |
| Dec 31, 2021 | 48.25 Mn |
| Sep 30, 2021 | 56.39 Mn |
| Jun 30, 2021 | 65.22 Mn |
| Mar 31, 2021 | 48.43 Mn |